Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - metoprolol tartrate, quantity: 50 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; lactose monohydrate; hypromellose; magnesium stearate; iron oxide red; croscarmellose sodium; macrogol 400; microcrystalline cellulose; sodium starch glycollate; titanium dioxide; purified talc; pregelatinised maize starch - hypertension: as monotherapy or for use in combination with other antihypertensives.,angina pectoris: for long-term prophylaxis. glyceryl trinitrate should be employed if necessary for alleviating acute attacks.,confirmed or suspected myocardial infarction.,prevention of migraine.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - bisoprolol fumarate, quantity: 2.5 mg - tablet, film coated - excipient ingredients: maize starch; colloidal anhydrous silica; microcrystalline cellulose; crospovidone; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - bisoprolol fumarate, quantity: 5 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; iron oxide yellow; microcrystalline cellulose; maize starch; crospovidone; titanium dioxide; hypromellose; macrogol 400 - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - bisoprolol fumarate, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; iron oxide yellow; crospovidone; magnesium stearate; maize starch; iron oxide red; titanium dioxide; hypromellose; macrogol 400 - treatment of stable chronic moderate to severe heart failure in addition to ace inhibitors, and diuretics, and optionally cardiac glycosides

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - riluzole, quantity: 50 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; microcrystalline cellulose; calcium phosphate; croscarmellose sodium; colloidal anhydrous silica; purified water; titanium dioxide; macrogol 400 - riluzole is indicated for the treatment of patients with amyotrophic lateral sclerosis (als)

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - riluzole, quantity: 50 mg - tablet, film coated - excipient ingredients: calcium phosphate; microcrystalline cellulose; hypromellose; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; purified water; titanium dioxide; macrogol 400 - riluzole is indicated for the treatment of patients with amyotrophic lateral sclerosis (als)

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - riluzole, quantity: 50 mg - tablet, film coated - excipient ingredients: purified water; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica; hypromellose; microcrystalline cellulose; calcium phosphate; titanium dioxide; macrogol 400 - riluzole is indicated for the treatment of patients with amyotrophic lateral sclerosis (als)

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - clopidogrel besilate, quantity: 111.86 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: lactose; microcrystalline cellulose; crospovidone; glyceryl behenate; purified talc; titanium dioxide; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease.,acute coronary syndrome,clopidogrel gh is indicated in combination with aspirin for patients with:,- unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel gh is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent),- st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - clopidogrel besilate, quantity: 111.86 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: lactose; microcrystalline cellulose; crospovidone; glyceryl behenate; purified talc; titanium dioxide; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease.,acute coronary syndrome,clopidogrel gh is indicated in combination with aspirin for patients with:,- unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel gh is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent),-st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risperidone, quantity: 2 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; hypromellose; microcrystalline cellulose; propylene glycol; magnesium stearate; titanium dioxide; lactose monohydrate; sunset yellow fcf aluminium lake; sodium lauryl sulfate; purified talc; maize starch - treatment of schizophrenia and related psychoses. . short term treatment of acute mania associated with bipolar 1 disorder. . treatment of behavioural disturbances in dementia. . treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent. . treatment of behavioural disorders associated with autism in children and adolescents.